Persistence of weekly alendronate: A real-world study in Croatia

Clinical Rheumatology

Volumn 27, Issue 5, 2008, Pages 651-653

  Grazio, Simeon ^a   Babic Naglic, Durda ^b   Kehler, Tatjana ^c   Curkovic, Bozidar ^b  

^a SESTRE MILOSRDNICE UNIVERSITY HOSPITAL   (Croatia)

^b KBC Zagreb   (Croatia)

^c Thalassotherapy Hospital   (Croatia)

Author keywords

Adherence; Alendronate; Bisphosphonate; Osteoporosis; Persistence; Weekly therapy

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE;

AGE; AGED; ARTICLE; COMORBIDITY; CORRELATION ANALYSIS; CROATIA; CULTURAL FACTOR; DRUG EFFICACY; FEMALE; FRACTURE; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; OSTEOPOROSIS; OUTPATIENT DEPARTMENT; PATIENT ATTITUDE; PATIENT COMPLIANCE; PATIENT PERSISTENCE; PRESCRIPTION; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SELF REPORT; SOCIAL ASPECT; TABLET;

AGED; ALENDRONATE; BONE DENSITY CONSERVATION AGENTS; CROATIA; FEMALE; HUMANS; MALE; MIDDLE AGED; OSTEOPOROSIS; PATIENT COMPLIANCE;

EID: 41849146452     PISSN: 07703198     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10067-007-0827-3     Document Type: Article

References (13)

1. Berg JS, Dischler J, Wagner DJ et al (1993) Medication compliance: A healthcare problem. Ann Pharmacother 27:S1-24
2. Solomon DH, Avorn J, Katz JN et al (2005) Compliance with osteoporosis medications. Arch Intern Med 165:1414-1419
3. Eastell R, Garnero P, Vrijens B et al (2003) Influence of patient compliance with risedronate therapy on bone turnover marker and bone mineral density response: The impact study. Calc Tissue Int 72:408
4. Yood RA, Emani S, Reed JI et al (2003) Compliance with pharmacologic therapy for osteoporosis. Osteoporosis Int 14:965-968
5. Sebaldt RJ, Shane LG, Pham BZ et al (2004) Impact of non-compliance and non-persistence with daily bisphosphonates on longer-term effectiveness outcomes in patients with osteoporosis treated in tertiary specialist care. Ann Rheum Dis 63(Suppl 1):96
6. Caro JJ, Ishak KJ, Huybrechts KF et al (2004) The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporosis Int 15:1003-1008
7. Rossini M, Bianchi G, Di Munno O et al (2006) Determinants of adherence to osteoporosis treatment in clinical practice. Osteoporosis Int 17:914-921
8. Tosteson AN, Grove MR, Hammond CS et al (2003) Early discontinuation of treatment of osteoporosis. Am J Med 115:209-216
9. McCoombs JS, Thiebaud P, McLaughlin-Miley C, Shi J (2004) Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas 48:271-287
10. Recker RR, Gallagher R, MacCosbe PE (2005) Effect of dosing frequency of bisphosphonate medication adherence in a large longitudinal cohort of women. Mayo Clin Proc 80:856-861
11. Cramer JA, Amonkar MM, Hebborn A, Altman R (2005) Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin 21:1453-1460
12. Sunyecs J, Highlands L, Gallagher R et al (2004) Days of therapy improve with weekly bisphosphonates dosing, but remain inadequate. Presented at the North American Menopause Society, October 6-9, 2004, Washington DC. Abstract 114, poster P126
13. Claxton AJ, Cramer J, Pierce C (2001) A systematic review of the association between dose regimens and medication compliance. Clin Ther 23:1296-310